SAN DIEGO, May 27, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive
Officer of Neurocrine Biosciences, will be presenting at the
Jefferies 2015 Healthcare Conference in New York City.
The live presentation takes place on Tuesday, June 2 at 3:00pm
ET (12:00pm PT). The
presentation will be webcast and may be accessed on the Company's
website at http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial
rights to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company. Neurocrine Biosciences, Inc. news
releases are available through the Company's website via the
internet at http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-jefferies-2015-healthcare-conference-300089669.html
SOURCE Neurocrine Biosciences, Inc.